In May 2020, the FDA approved atezolizumab, an anti-PD-L1 antibody, and the VEGF-neutralizing antibody bevacizumab for the first-line treatment of patients with unresectable or metastatic HCC (Figure 1), marking the beginning of the era of immunotherapy for advanced HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.